a public good project by the
Synthesis
Company
of California

© 2026

Jin Kyung Rho | doi.page

0 works0 citations0 h-index

Jin Kyung Rho

Ulsan College(KR)Asan Medical Center(KR)University of Ulsan(KR)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Mechanisms and Therapy, HER2/EGFR in Cancer Research, Cancer therapeutics and mechanisms

Most-Cited Works

→ Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer(2012)1,207 cited
→ Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer(2019)378 cited
→ RETRACTED ARTICLE: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers(2011)365 cited
→ Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line(2008)219 cited
→ Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells(2012)201 cited
→ Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs(2010)196 cited

→ MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation(2013)

144 cited

→ p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung Cancer(2007)129 cited

→ Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation(2013)112 cited

→ Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4(2020)104 cited